Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joleen T White

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Bioanalysis|October 24, 2012
Free and total biotherapeutic evaluation in chromatographic assays: interference from targets and immunogenicityJoleen T White, Leo E Bonilla
Bioanalysis|September 1, 2011
Understanding and mitigating impact of immunogenicity on pharmacokinetic assaysJoleen T White, Michaela Golob, Jeffrey Sailstad
Bioanalysis|June 26, 2015
Incurred sample reproducibility and stability assessment in a cell-based drug concentration assayJoleen T White, Mary Crossman, Meena Subramanyam
The AAPS Journal|January 30, 2020
Immunogenicity Risk Assessment for PEGylated TherapeuticsJohanna R Mora, Joleen T White, Stephen L DeWall
Biochemistry|June 9, 2004
Transthyretin aggregation under partially denaturing conditions is a downhill polymerizationAmy R Hurshman, Joleen T White, Evan T Powers, et al.
Bioanalysis|November 7, 2015
Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1aJoleen T White, Mary Crossman, Kelly Richter, et al.
The AAPS Journal|November 6, 2021
Immunogenicity Risk Assessment for Multi-specific TherapeuticsMark A Kroenke, Mark N Milton, Seema Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 17, 2006
R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppressionYoshiki Sekijima, Maria T Dendle, R Luke Wiseman, et al.
Bioanalysis|April 29, 2020
Strategies for method comparison when changes in the immunogenicity method are needed within a clinical programJohanna R Mora, Joleen T White, Shannon D Chilewski, et al.
The AAPS Journal|July 9, 2008
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)Joleen T White, Lisa Argento Martell, Andrea Van Tuyl, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Bioanalysis|October 24, 2012
Free and total biotherapeutic evaluation in chromatographic assays: interference from targets and immunogenicityJoleen T White, Leo E Bonilla
Bioanalysis|September 1, 2011
Understanding and mitigating impact of immunogenicity on pharmacokinetic assaysJoleen T White, Michaela Golob, Jeffrey Sailstad
Bioanalysis|June 26, 2015
Incurred sample reproducibility and stability assessment in a cell-based drug concentration assayJoleen T White, Mary Crossman, Meena Subramanyam
The AAPS Journal|January 30, 2020
Immunogenicity Risk Assessment for PEGylated TherapeuticsJohanna R Mora, Joleen T White, Stephen L DeWall
Biochemistry|June 9, 2004
Transthyretin aggregation under partially denaturing conditions is a downhill polymerizationAmy R Hurshman, Joleen T White, Evan T Powers, et al.
Bioanalysis|November 7, 2015
Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN-β-1aJoleen T White, Mary Crossman, Kelly Richter, et al.
The AAPS Journal|November 6, 2021
Immunogenicity Risk Assessment for Multi-specific TherapeuticsMark A Kroenke, Mark N Milton, Seema Kumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 17, 2006
R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppressionYoshiki Sekijima, Maria T Dendle, R Luke Wiseman, et al.
Bioanalysis|April 29, 2020
Strategies for method comparison when changes in the immunogenicity method are needed within a clinical programJohanna R Mora, Joleen T White, Shannon D Chilewski, et al.
The AAPS Journal|July 9, 2008
Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase)Joleen T White, Lisa Argento Martell, Andrea Van Tuyl, et al.
Pageof 3